Balance Sheet Components

3 Months Ended

Mar. 31, 2023

Balance Sheet Components

Balance Sheet Components

6. Balance Sheet Components

Credit Losses

The following is a roll-forward of the allowances for credit losses related to trade accounts receivable and other receivables for the three months ended March 31, 2023 and 2022:

	Three Months Ended
	March 31,
	2023		2022
		(in thousands)
Beginning balance	$	3,830	$	2,429
Provision for credit losses		1,304		331
Write-offs		—		(368)
Total	$	5,134	$	2,392

Property and Equipment, net

The Company’s property and equipment consisted of the following:

		March 31,		December 31,
	Useful Life	2023		2022
		(in thousands)
Machinery and equipment	3-5 years	$	74,852	$	66,262
Computer equipment	3 years		1,700		1,308
Purchased and capitalized software held for internal use	3 years		6,739		5,464
Leasehold improvements	Lesser of useful life or lease term		29,761		29,747
Construction-in-process			28,148		25,370
			141,200		128,151
Less: Accumulated depreciation and amortization			(40,613)		(35,698)
Total Property and Equipment, net		$	100,587	$	92,453

The Company’s long-lived assets are mostly located in the United States.

During the three months ended March 31, 2023, the increase in net property and equipment was due to expansion projects and purchases of new equipment for the Company’s laboratories located in Texas and California to expand testing capabilities, offset by depreciation expense of $5.1 million recorded in the three months ended March 31, 2023 Depreciation expense of $3.0 million was recorded in the three months ended March 31, 2022. The Company did not incur any impairment charges during the three months ended in either March 31, 2023 or 2022.

Other Accrued Liabilities

The Company’s other accrued liabilities consisted of the following:

	March 31,		December 31,
	2023		2022
	(in thousands)
Reserves for refunds to insurance carriers	$	14,271	$	18,948
Accrued charges for third-party testing		13,707		17,036
Testing and laboratory materials from suppliers		15,203		13,281
Marketing and corporate affairs		7,604		8,943
Legal, audit and consulting fees		21,793		36,710
Accrued shipping charges		1,004		485
Sales and income tax payable		5,091		4,319
Accrued third-party service fees		10,184		6,631
Clinical trials and studies		11,373		23,301
Operating lease liabilities, current portion		9,308		7,639
Property and equipment purchases		1,777		1,821
Other accrued interest		2,695		1,078
Other accrued expenses		4,628		4,022
Total other accrued liabilities	$	118,638	$	144,214

Reserves for refunds to insurance carriers include overpayments from and amounts to be refunded to insurance carriers, and additional amounts that the Company estimates for potential refund requests during the period. When the Company releases these previously accrued amounts, they are recognized as product revenues in the condensed statements

of operations and comprehensive loss. The following table summarizes the reserve balance and activities for refunds to insurance carriers for the three months ended March 31, 2023:

	March 31,		March 31,
	2023		2022
	(in thousands)
Beginning balance	$	18,948	$	17,210
Additional reserves		2,384		3,502
Refunds to carriers		(350)		(1,991)
Reserves released to revenue		(6,711)		(1,395)
Ending balance	$	14,271	$	17,326